Monitoring of minimal residual disease in leukemia, advantages and pitfalls

Giovanni Cazzaniga, Giuseppe Gaipa, Vincenzo Rossi, Andrea Biondi

Research output: Contribution to journalArticle

Abstract

The term 'minimal residual disease' (MRD) defines the level of disease detectable in patients in clinical remission during therapy, below the detection limit of conventional methods. Very sensitive methods can be used, able to identify one leukemic cell out of 10,000 normal lymphocytes. In vivo measurements of leukemia cytoreduction reflect the combined effect of clinical and biological variables, thus providing direct information on the effectiveness of treatment in each patient. Thus, these methods can potentially be used for tailoring treatment and personalize the cure. Although MRD studies are becoming an integral part of the modern management of patients with leukemia, several parameters are critical for the application and interpretation of MRD studies, including therapeutic context, timing of sampling, target genes and sensitivity of the polymerase chain reaction (PCR) assay, inter-laboratory standardization (particularly relevant in multicenter studies), selection of patients, retrospective or prospective nature of the study. Methodologies and pitfalls as well as results of clinical uses of MRD will be reviewed in this article by selecting significant examples of its clinical impact in the management of patients with leukemia.

Original languageEnglish
Pages (from-to)512-521
Number of pages10
JournalAnnals of Medicine
Volume38
Issue number7
DOIs
Publication statusPublished - Nov 1 2006

Fingerprint

Residual Neoplasm
Leukemia
Patient Selection
Multicenter Studies
Limit of Detection
Therapeutics
Prospective Studies
Lymphocytes
Polymerase Chain Reaction
Genes

Keywords

  • Leukemia
  • Minimal residual disease
  • Treatment stratification

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Monitoring of minimal residual disease in leukemia, advantages and pitfalls. / Cazzaniga, Giovanni; Gaipa, Giuseppe; Rossi, Vincenzo; Biondi, Andrea.

In: Annals of Medicine, Vol. 38, No. 7, 01.11.2006, p. 512-521.

Research output: Contribution to journalArticle

Cazzaniga, Giovanni ; Gaipa, Giuseppe ; Rossi, Vincenzo ; Biondi, Andrea. / Monitoring of minimal residual disease in leukemia, advantages and pitfalls. In: Annals of Medicine. 2006 ; Vol. 38, No. 7. pp. 512-521.
@article{6aa6f18e2399443b80f311fcc4993a08,
title = "Monitoring of minimal residual disease in leukemia, advantages and pitfalls",
abstract = "The term 'minimal residual disease' (MRD) defines the level of disease detectable in patients in clinical remission during therapy, below the detection limit of conventional methods. Very sensitive methods can be used, able to identify one leukemic cell out of 10,000 normal lymphocytes. In vivo measurements of leukemia cytoreduction reflect the combined effect of clinical and biological variables, thus providing direct information on the effectiveness of treatment in each patient. Thus, these methods can potentially be used for tailoring treatment and personalize the cure. Although MRD studies are becoming an integral part of the modern management of patients with leukemia, several parameters are critical for the application and interpretation of MRD studies, including therapeutic context, timing of sampling, target genes and sensitivity of the polymerase chain reaction (PCR) assay, inter-laboratory standardization (particularly relevant in multicenter studies), selection of patients, retrospective or prospective nature of the study. Methodologies and pitfalls as well as results of clinical uses of MRD will be reviewed in this article by selecting significant examples of its clinical impact in the management of patients with leukemia.",
keywords = "Leukemia, Minimal residual disease, Treatment stratification",
author = "Giovanni Cazzaniga and Giuseppe Gaipa and Vincenzo Rossi and Andrea Biondi",
year = "2006",
month = "11",
day = "1",
doi = "10.1080/07853890600978123",
language = "English",
volume = "38",
pages = "512--521",
journal = "Annals of Medicine",
issn = "0785-3890",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Monitoring of minimal residual disease in leukemia, advantages and pitfalls

AU - Cazzaniga, Giovanni

AU - Gaipa, Giuseppe

AU - Rossi, Vincenzo

AU - Biondi, Andrea

PY - 2006/11/1

Y1 - 2006/11/1

N2 - The term 'minimal residual disease' (MRD) defines the level of disease detectable in patients in clinical remission during therapy, below the detection limit of conventional methods. Very sensitive methods can be used, able to identify one leukemic cell out of 10,000 normal lymphocytes. In vivo measurements of leukemia cytoreduction reflect the combined effect of clinical and biological variables, thus providing direct information on the effectiveness of treatment in each patient. Thus, these methods can potentially be used for tailoring treatment and personalize the cure. Although MRD studies are becoming an integral part of the modern management of patients with leukemia, several parameters are critical for the application and interpretation of MRD studies, including therapeutic context, timing of sampling, target genes and sensitivity of the polymerase chain reaction (PCR) assay, inter-laboratory standardization (particularly relevant in multicenter studies), selection of patients, retrospective or prospective nature of the study. Methodologies and pitfalls as well as results of clinical uses of MRD will be reviewed in this article by selecting significant examples of its clinical impact in the management of patients with leukemia.

AB - The term 'minimal residual disease' (MRD) defines the level of disease detectable in patients in clinical remission during therapy, below the detection limit of conventional methods. Very sensitive methods can be used, able to identify one leukemic cell out of 10,000 normal lymphocytes. In vivo measurements of leukemia cytoreduction reflect the combined effect of clinical and biological variables, thus providing direct information on the effectiveness of treatment in each patient. Thus, these methods can potentially be used for tailoring treatment and personalize the cure. Although MRD studies are becoming an integral part of the modern management of patients with leukemia, several parameters are critical for the application and interpretation of MRD studies, including therapeutic context, timing of sampling, target genes and sensitivity of the polymerase chain reaction (PCR) assay, inter-laboratory standardization (particularly relevant in multicenter studies), selection of patients, retrospective or prospective nature of the study. Methodologies and pitfalls as well as results of clinical uses of MRD will be reviewed in this article by selecting significant examples of its clinical impact in the management of patients with leukemia.

KW - Leukemia

KW - Minimal residual disease

KW - Treatment stratification

UR - http://www.scopus.com/inward/record.url?scp=33751119905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751119905&partnerID=8YFLogxK

U2 - 10.1080/07853890600978123

DO - 10.1080/07853890600978123

M3 - Article

C2 - 17101542

AN - SCOPUS:33751119905

VL - 38

SP - 512

EP - 521

JO - Annals of Medicine

JF - Annals of Medicine

SN - 0785-3890

IS - 7

ER -